ArticleMolecular brain2014
Vorinostat positively regulates synaptic plasticity genes expression and spine density in HIV infected neurons: role of nicotine in progression of HIV-associated neurocognitive disorder.
Article in Molecular brain, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 37 citations in OpenAlex.
- Article
- The impacts of tobacco and nicotine on HIV-1 infection, inflammation, and the blood-brain barrier in the central nervous system.Frontiers in pharmacology · 2024Review
- Review
- Repurposing Vorinostat for the Treatment of Disorders Affecting Brain.Neuromolecular medicine · 2021Review
- Systematic analysis to identify transcriptome-wide dysregulation of Alzheimer's disease in genes and isoforms.Human genetics · 2021Article
- Characterization of Nanodiamond-based anti-HIV drug Delivery to the Brain.Scientific reports · 2018Article
- Immune activation and neuroinflammation in alcohol use and HIV infection: evidence for shared mechanisms.The American journal of drug and alcohol abuse · 2017Review
- Histone Deacetylase Inhibitors Are Protective in Acute but Not in Chronic Models of Ototoxicity.Frontiers in cellular neuroscience · 2017Article
- Common gene-network signature of different neurological disorders and their potential implications to neuroAIDS.PloS one · 2017Article
- Potentiation of Surface Stability of AMPA Receptors by Sulfhydryl Compounds: A Redox-Independent Effect by Disrupting Palmitoylation.Neurochemical research · 2016Article
- Inhibitors of Histone Deacetylases Attenuate Noise-Induced Hearing Loss.Journal of the Association for Research in Otolaryngology : JARO · 2016Article
- Getting into the brain: Potential of nanotechnology in the management of NeuroAIDS.Advanced drug delivery reviews · 2016Review
- Coupling of transient near infrared photonic with magnetic nanoparticle for potential dissipation-free biomedical application in brain.Scientific reports · 2016Article
- Magnetic nanotherapeutics for dysregulated synaptic plasticity during neuroAIDS and drug abuse.Molecular brain · 2016Review
- Editorial: HIV and Illicit Drugs of Abuse.Frontiers in microbiology · 2016Article
- Tobacco Use, Use Disorders, and Smoking Cessation Interventions in Persons Living With HIV.Current HIV/AIDS reports · 2015Review
- Therapeutical Neurotargeting via Magnetic Nanocarrier: Implications to Opiate-Induced Neuropathogenesis and NeuroAIDS.Journal of biomedical nanotechnology · 2015Article
- Nicotine attenuates the effect of HIV-1 proteins on the neural circuits of working and contextual memories.Molecular brain · 2015Article
- Curcumin improves synaptic plasticity impairment induced by HIV-1gp120 V3 loop.Neural regeneration research · 2015Article
- Preparation and characterization of anti-HIV nanodrug targeted to microfold cell of gut-associated lymphoid tissue.International journal of nanomedicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundHIV-associated neurocognitive disorder (HAND) is characterized by development of cognitive, behavioral and motor abnormalities, and occurs in approximately 50% of HIV infected individuals. In the United States, the prevalence of cigarette smoking ranges from 35-70% in HIV-infected individuals compared to 20% in general population. Cognitive impairment in heavy cigarette smokers has been well reported. However, the synergistic effects of nicotine and HIV infection and the underlying mechanisms in the development of HAND are unknown.
resultsIn this study, we explored the role of nicotine in the progression of HAND using SK-N-MC, a neuronal cell line. SK-N-MC cells were infected with HIV-1 in the presence or absence of nicotine for 7 days. We observed significant increase in HIV infectivity in SK-N-MC treated with nicotine compared to untreated HIV-infected neuronal cells. HIV and nicotine synergize to significantly dysregulate the expression of synaptic plasticity genes and spine density; with a concomitant increase of HDAC2 levels in SK-N-MC cells. In addition, inhibition of HDAC2 up-regulation with the use of vorinostat resulted in HIV latency breakdown and recovery of synaptic plasticity genes expression and spine density in nicotine/HIV alone and in co-treated SK-N-MC cells. Furthermore, increased eIF2 alpha phosphorylation, which negatively regulates eukaryotic translational process, was observed in HIV alone and in co-treatment with nicotine compared to untreated control and nicotine alone treated SK-N-MC cells.
conclusionsThese results suggest that nicotine and HIV synergize to negatively regulate the synaptic plasticity gene expression and spine density and this may contribute to the increased risk of HAND in HIV infected smokers. Apart from disrupting latency, vorinostat may be a useful therapeutic to inhibit the negative regulatory effects on synaptic plasticity in HIV infected nicotine abusers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.